1751-553X/asset/bannerforeground.gif?v=1&s=1e3317ecb1bc5a6d1bce48f4b4d85d110803591e)
The JAK2V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis
Article first published online: 6 AUG 2007
DOI: 10.1111/j.1751-553X.2007.00973.x
© 2007 The Authors. Journal compilation © 2007 Blackwell Publishing Ltd
Additional Information
How to Cite
GOULDING, C., UTTENTHAL, B., FORONI, L., DUKE, V., TRAORE, A., KOTTARIDIS, P., HOFFBRAND, A. V., PATCH, D. and MCNAMARA, C. (2008), The JAK2V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. International Journal of Laboratory Hematology, 30: 415–419. doi: 10.1111/j.1751-553X.2007.00973.x
Publication History
- Issue published online: 4 SEP 2008
- Article first published online: 6 AUG 2007
- Received 26 February 2007; accepted for publication 25 June 2007
- Abstract
- Article
- References
- Cited By
Keywords:
- Myeloproliferative syndromes;
- thrombosis
Summary
Clinically latent myeloproliferative disorders (MPDs) are important causes of what would otherwise be considered idiopathic hepatic (HVT) or portal vein thrombosis (PVT). They may be difficult to diagnose initially because the peripheral blood count may be normal at the time of thrombosis. A strong association between an activating mutation of the gene encoding one of the Janus kinase family of tyrosine kinases (JAK2V617F) and the Philadelphia chromosome-negative MPDs has been identified. We have studied 19 patients with unexplained HVT or PVT and tested for JAK2V617F. Fourteen (74%) of the 19 patients were heterozygous for JAK2V617F but did not meet diagnostic criteria for a MPD at the time of presentation with thrombosis. Prolonged follow-up established the presence of an overt MPD in 13 of the 14 patients after a median duration of 38 months. We recommend testing for JAK2V617F in all patients with unexplained HVT or PVT, to identify latent MPDs and prevent potential complications.